N6-Cycloalkyl- and N6-Bicycloalkyl-C5′(C2′)-modified Adenosine Derivatives as High-Affinity and Selective Agonists at the Human A1 Adenosine Receptor with Antinociceptive Effects in Mice

Department of Chemical Sciences, University of Camerino, 62032 Camerino, Italy.
Journal of Medicinal Chemistry (Impact Factor: 5.45). 04/2009; 52(8). DOI: 10.1021/jm801456g


To further investigate new potent and selective human A1 adenosine receptor agonists, we have synthesized a series of 5′-chloro-5′-deoxy- and 5′-(2-fluorophenylthio)-5′-deoxy-N6-cycloalkyl(bicycloalkyl)-substituted adenosine and 2′-C-methyladenosine derivatives. These compounds were evaluated for affinity and efficacy at human A1, A2A, A2B, and A3 adenosine receptors. In the series of N6-cyclopentyl- and N6-(endo-norborn-2-yl)adenosine derivatives, 5′-chloro-5′-deoxy-CPA (1) and 5′-chloro-5′-deoxy-(±)-ENBA (3) displayed the highest affinity in the subnanomolar range and relevant selectivity for hA1 vs the other human receptor subtypes. The higher affinity and selectivity of 5′-chloro-5′-deoxyribonucleoside derivatives 1 and 3 for hA1 AR vs hA3 AR compared to that of the parent 5′-hydroxy compounds CPA and (±)-ENBA was rationalized by a molecular modeling analysis. 5′-Chloro-5′-deoxy-(±)-ENBA, evaluated for analgesic activity in the formalin test in mice, was found to inhibit the first or the second phases of the nocifensive response induced by intrapaw injection of formalin at doses ranging between 1 and 2 mg/kg i.p.

Download full-text


Available from: Riccardo Petrelli, Oct 09, 2015
35 Reads
  • Source
    • "The following pharmacological agents were used (from Sigma- Aldrich, Milan, Italy): (5R,10S)-(−)-5-methyl-10,11-dihydro-5H- dibenzo[a,d]cylcohepten-5,10-imine maleate (MK-801), 6-cyano-7- nitroquinoxaline-2,3-dione disodium salt hydrate (CNQX), papaverine, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), SCH 23390, (±)-1-phe- nyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine-7,8-diol hydrobromide (SKF 38393), 6-chloro-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine- 7,8-diol (SKF 81297), 6-hydroxydopamine hydrochloride (6-OHDA), and 3,4-dihydroxy-L-phenylalanine (L-DOPA) (administered i.p. together with benserazide hydrochloride). AE90074 was a kind gift of Dr Jan Kehler, Lundbeck (Copenhagen, Denmark) and N 6 -(±)-endo-norbornyl- 9H-(5-chloro-5-deoxy-β-D-ribofuranosyl)adenine (5′-chloro-5′-deoxy- (±)-ENBA, 5′Cl5′d-(±)-ENBA) was synthesized at the University of Camerino, as previously reported (Franchetti et al., 2009). All drugs used in the electrophysiological experiments were bath applied, while those for the behavioral experiments were dissolved in saline and injected i.p. in a volume of 10 ml/kg, except for 5′Cl5′d-(±)-ENBA that was dissolved in 5% DMSO. "
    [Show abstract] [Hide abstract]
    ABSTRACT: γ-Aminobutyric acid A receptor (GABAAR)-mediated postsynaptic currents were recorded in brain slices from substantia nigra pars reticulate neurons. The selective adenosine A1 receptor (A1R) antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), increased the frequency, but not the amplitude of spontaneous inhibitory post-synaptic currents (IPSCs) in the presence of the dopamine D1 receptor agonist SKF 38393 (SKF) and phosphodiesterase 10A inhibitors (papaverine or AE90074). Under these conditions, DPCPX also increased the amplitude of evoked IPSCs (eIPSCs). The effect of DPCPX was also examined in a mouse model of Parkinson's disease (PD), generated by unilateral denervation of the dopaminergic input to the striatum. In this model, SKF alone was sufficient to increase sIPSCs frequency and eIPSCs amplitude, and these effects were not potentiated by DPCPX. To confirm a depressive effect of A1Rs on the synaptic release of GABA we used the selective A1R agonist 5′-chloro-5′-deoxy-N6-(±)-(endo-norborn-2-yl)adenosine (5′Cl5′d-(±)-ENBA) which has limited peripheral actions. We found that 5′Cl5′d-(±)-ENBA decreased sIPSCs frequency, without affecting their amplitude, and decreased eIPSCs amplitude. Importantly, in the PD mouse model, 5′Cl5′d-(±)-ENBA prevented the increase in sIPSC frequency and eIPSC amplitude produced by SKF. Since exaggerated DA transmission along the striato-nigral pathway is involved in the motor complications (e.g. dyskinesia) caused by prolonged and intermittent administration of l-DOPA, we examined the effect of A1R activation in mice with unilateral DA denervation. We found that 5′Cl5′d-(±)-ENBA, administered in combination with l-DOPA, reduced the development of abnormal involuntary movements. These results indicate the potential benefit of A1R agonists for the treatment of l-DOPA-induced dyskinesia and hyperkinetic disorders providing a mechanistic framework for the study of the interaction between DA and adenosine in the striatonigral system.
    Experimental Neurology 08/2014; 261. DOI:10.1016/j.expneurol.2014.08.022 · 4.70 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Racemic 1′,4′-dimethyladenosine was prepared according to a stereoselective sequence from 2,5-dimethyl furan and vinylene carbonate. This sequence is short and efficient (nine steps) and relies on the desymmetrization of a meso diol, followed by the glycosylation of the anomeric position. The latter reaction was thoroughly studied, as it is the key step of the sequence, and very particular reactivity of the 1′,4′-dimethylated sugars was observed. Secondary reactions took place according to original mechanisms and delivered original byproducts.
    European Journal of Organic Chemistry 01/2011; 2011(2):319 - 326. DOI:10.1002/ejoc.201001216 · 3.07 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: This review summarizes current knowledge of adenosine analogues and conjugates with promising therapeutic properties. Adenosine is a signaling molecule that triggers numerous physiological responses. It acts through the adenosine receptors (ARs), belonging to the family of G-protein-coupled receptors and widely distributed throughout the body. Moreover, adenosine is involved in key biochemical processes as a part of ATP, the universal energy currency. Thus, compounds that are analogues of adenosine and its conjugates have been extensively studied as potential therapeutics. Many inhibitors of ARs are in clinical trials as promising agents in treatment of inflammation, type 2 diabetes, arrhythmia and as vasodilators used in the myocardial perfusion imaging (MPI) stress test. Furthermore, adenosine analogues revealed high efficacy as enzyme inhibitors, tested for antitrypanosomal action and as bivalent ligands and adenosine-oligoarginine conjugates as inhibitors of protein kinases.
    Pharmacological reports: PR 05/2011; 63(3):601-17. DOI:10.1016/S1734-1140(11)70573-4 · 1.93 Impact Factor
Show more